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CT angiography (CTA) has been widely used to detect endoleak following endovascular aneurysm repair, but is
expensive and there is a risk of kidney damage because of the X-ray contrast media. 3D contrast enhanced
ultrasound (CEUS) is at least as sensitive to endoleak, is less expensive, and may detect endoleaks missed by
CTA. As 3D CEUS has no known toxicity, we plan to replace CTA with 3D CEUS; a major clinical trial is indicated to
determine whether 3D CEUS is more sensitive than CTA.Objective: CT angiography (CTA) for endovascular aneurysm repair (EVAR) surveillance involves irradiation and
nephrotoxic X-ray contrast agents. Three-dimensional contrast enhanced ultrasound (3D CEUS) is a novel imaging
technique that may be more sensitive to blood ﬂow detection than CTA or 2D CEUS. 3D CEUS utilises positional
information from magnetic ﬁeld emitters to assemble all ultrasound reﬂections into a high-deﬁnition image. We
compared 3D CEUS with CTA for the detection of endoleak and aneurysm expansion following EVAR.
Methods: 3D CEUS (Curefab), 2D CEUS (Philips IU22), and CTA were compared in 30-paired images from 23
patients. Sensitivity, speciﬁcity, positive, and negative predictive value were calculated for 2D and 3D CEUS
against CTA as the ‘gold standard’. Pearson correlation was used to compare aneurysm sac diameter. Data were
analysed using SPSS version 19.0.
Results: 30 paired 3D CEUS and CTA images were analysed from 23 patients. Endoleaks were detected in 17
images with CTA, 18 on 2D CEUS, and 18 on 3D CEUS. The sensitivity, speciﬁcity, positive, and negative predictive
values of 3D CEUS to detect endoleak were 100%, 92%, 94%, and 100%, respectively. There was excellent
correlation (r ¼ 0.935; p  .0001) between CTA and 3D CEUS for AAA sac diameter. Only 3D CEUS detected the
inﬂow and outﬂow arteries in all 18 scans with endoleak. 2D CEUS detected the inﬂow in 16 (88.8%) and CTA on
12 (66.6%) of the images.
Conclusion: 3D CEUS may be more sensitive to endoleak following EVAR than either 2D CEUS or CTA.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Endovascular aneurysm repair (EVAR) has a lower operative
mortality for elective abdominal aortic aneurysm (AAA)
repair than open surgery.1e3 This has become increasingly
accepted, accounting for over 70% of AAA repairs currently
performed.4 The disadvantage of EVAR is the need for life-
long surveillance to monitor stent-graft related complica-
tions.5 Surveillance is traditionally by computed tomo-
graphic angiography (CTA), which requires irradiation andrresponding author. C.N. McCollum, Institute of Cardiovascular Sci-
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//dx.doi.org/10.1016/j.ejvs.2014.02.002nephrotoxic X-ray contrast media.6 More recently, duplex
ultrasound has been proposed as a safe and inexpensive
alternative.7
Conventional duplex ultrasound has been reported to
be effective at detecting endoleaks after EVAR that were
not identiﬁed by intraoperative completion angiography.8
Contrast enhanced ultrasound (CEUS), using sulphur
hexaﬂuoride microbubbles, is reported to detect endo-
leaks missed by CTA and is safe with minimal side ef-
fects.9e11 Three-dimensional contrast enhanced
ultrasound (3D CEUS) is a novel technology that utilises
positional information from magnetic ﬁeld emitters to
assemble all ultrasound reﬂections into a high-deﬁnition
3D image. This technology is used in the same way as
standard duplex imaging, but produces higher quality
images. Unlike standard CEUS, angiography, or CTA, 3D
CEUS detects the source (Type I, III or II) of any endoleak
with conﬁdence.
Figure 1. 3D contrast enhanced ultrasound (3D CEUS) showing an
EVAR at 2 years with no endoleak.
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The aim of this prospective pilot study was to assess the
clinical utility and accuracy of 3D CEUS compared with
standard 2D CEUS and CTA in post EVAR-surveillance, and
its inﬂuence on patient management. The primary outcome
measure was the detection of endoleak and its source.
METHODS
This pilot study was conducted at a single tertiary referral
vascular centre and was approved by the local research
ethics committee (REC number 13/NW/0485). Consecutive
subjects attending for CTA and 3D CEUS imaging who were
thought to possibly have an endoleak following an EVAR
were included in this study (n ¼ 23). The subjects were
recruited from the South Manchester EVAR surveillance
programme between May 2012 and May 2013. Subjects
who did not have paired CTA imaging were excluded. De-
mographic data were collected and all images were
reviewed by a research fellow and these were reported by
either an accredited vascular laboratory technologist (2D or
3D CEUS) or consultant interventional radiologist (CTA).
Our institution has a novel 3D ultrasound system (Cur-
efab, Munich, Germany) available for clinical use. 3D CEUS
and 2D CEUS were compared with CTA, which was
considered to be the ‘gold standard’.
3D contrast enhanced ultrasound technology
The Curefab 3D system comprises tracking sensors installed
in the transducer of a high-deﬁnition duplex Doppler ul-
trasound system (IU22- C5) and an electromagnetic box.
This technology uses a motion tracking mini-GPS (global
positioning system) with a magnetic ﬁeld emitter and two
tracking sensors that transform standard 2D CEUS images
into high-deﬁnition 3D format.12 These instruments utilise
positional information from magnetic ﬁeld emitters to place
and orientate the transducer probe precisely in time and
space. Unlike conventional ultrasound, where a small
number of representative 2D images taken from the many
thousand generated during an average 10 minute scan are
used for diagnosis, all the acquired 2D information is uti-
lised to construct a high-deﬁnition 3D image. The system’s
pattern recognition software and algorithms compare each
frame to a multitude of others to construct a single 3D
volume image within seconds (Figs. 1 and 2b). These are
dynamic images that may be manipulated by the operator
to interrogate any area of interest. The colour coding of the
stent-graft is added manually, by scrolling through the im-
ages in transverse and drawing around the graft at 3e5 mm
sections. The colour is based on a segmentation that the
user has to add manually by drawing planimetry contours.
Basically, the opacity of all voxels outside the segmentation
of the aneurysm sac will be reduced, whereas all voxels
inside the segmentation of the stent will be coloured. In
practice, it is only necessary to add the colour coding in
complex cases. Importantly, the 3D modality adds no extra
time to image acquisition and neither the mechanical nor
thermal index on the ultrasound machine are increased.2D and 3D CEUS images are acquired simultaneously by
the same vascular laboratory technologist without requiring
additional ultrasound contrast administration. The acquired
3D images can be interrogated subsequently and allow slow
playback enabling detailed interrogation of the vessels,
blood ﬂow, and the source of any endoleak.
The 3D system augments the 2D CEUS images, with the
2D CEUS identifying the direction of the ﬂow shown in a
cineloop displayed by the 3D system. The 3D reconstruction
enables the operator to view the path of the endoleak. The
ability to manoeuvre the 3D reconstruction and view the
images in sagittal, coronal, and transverse planes simulta-
neously without moving the probe, enables the operator to
accurately identify if ﬂow is within or outside the aneurysm
sac. Blood vessels lying adjacent to the aorta would not be
misidentiﬁed as inﬂow or outﬂow vessels.
2D contrast enhanced ultrasound
2D CEUS images were obtained using a duplex ultrasound
instrument (Philips IU22) with the C5-1 curved array
transducer.
2D and 3D CEUS image acquisition
With patients supine, the AAA and stent-graft were visual-
ised and traced to the proximal neck, which was measured
in cross-section and interrogated for potential endoleak
using low colour ﬂow velocity or power Doppler colour ﬂow
settings. The AAA diameter was measured using calipers
placed on the inner reﬂection of the anterior and posterior
walls; multiple transverse and antero-posterior (AP) mea-
surements were obtained and the maximum recorded. Af-
ter administration of sulphur hexaﬂuoride contrast
(SonoVue, Bracco, Milan, Italy; cost £48/-) into a peripheral
Figure 2. (A) CTA showing Type II endoleak. (B) 3D CEUS of same
subject showing a Type II endoleak (red arrows) ﬂowing from the
(a) inferior mesenteric artery (b) to a lumbar artery. The stent-graft
is coloured red by the 3D ultrasound software to distinguish ﬂow
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transverse section from the neck of the graft to the distal
stent-graft in the iliac arteries. If an endoleak was identiﬁed,
the inﬂow and outﬂow vessels were identiﬁed if possible.
The image acquisition for 2D and 3D CEUS is simultaneous
and takes 10e15 minutes, with subsequent analysis of the
3D images taking a further 5e10 minutes. AAA diameter
measurement was AP inner to inner. The images were
analysed independently by two fully trained vascular labo-
ratory technologists.
CTA imaging
All patients had paired CTA images as a part of their routine
EVAR surveillance protocol. These contrast enhanced im-
ages were obtained on a 16-slice helical scanner with a
1 mm slice thickness (Siemens Sensation, Siemens Medical,
Germany). CTA from the diaphragm to femoral heads was
performed with the patient supine. A dose of 100 mL of the
iodinated contrast medium Omnipaque 240 (iohexol,
240 mg/mL) was administered at a ﬂow rate of 3 mL/s. The
duration of imaging was 15e20 minutes. The diameter was
measured AP inner to inner. The estimated radiation dose
was 5.4 mSv or 300 dose length product.13
Statistics
Measures of accuracy relating to endoleak detection (cat-
egorical variable) including sensitivity, speciﬁcity, positive,
and negative predictive values were calculated using con-
tingency tables.14,15 Pearson’s correlation was used to
compare AAA diameter measured by 2D and 3D CEUS with
CTA. An interobserver reliability analysis using the Kappa
statistic was performed to determine consistency between
two observers to detect endoleak on 3D CEUS. A p-value
less than .05 (two sided) was considered signiﬁcant.
The data were analysed using SPSS version 19.0 statistical
software (SPSS Inc., Chicago, IL, USA). This pilot study will
provide guidance for the power calculations required to
perform future deﬁnitive studies.
RESULTS
Thirty paired 2D and 3D CEUS and CTA images were ana-
lysed from 23 patients. Paired images at different time in-
tervals were included in seven patients. Patient
demographics are shown in Table 1. The interval between
paired images was 3.9  2.7 (mean  SD) weeks. Endoleaks
were detected in 17 images with CTA, 18 on 2D CEUS, and
18 on 3D CEUS (Table 3). Assuming CTA to be a gold
standard, the sensitivity, speciﬁcity, positive, and negative
predictive values of 2D and 3D CEUS to detect endoleak
were 100%, 92%, 94%, and 100%, respectively (Table 2). 2D
and 3D CEUS had the same accuracy for the simple detec-
tion of an endoleak. There was an excellent correlation
(r ¼ .935; p  .0001; Fig. 3) between 3D CEUS and CTA forwithin the stent-graft from ﬂow outside (i) cross section (ii) lon-
gitudinal section (iii) oblique.
Table 1. Demographic characteristics.
Characteristics n ¼ 23
Age (years; mean  SD) 77.4  6
Gender
Female 12% (3)
Male 88% (22)
BMI (kg/m2; mean  SD) 29  4
Stent-graft
Bifurcated 80% (20)
Uniliac 20% (5)
EVAR
Elective 96% (24)
Emergency 4% (1)
Creatinine (mmol/L; mean  SD) 101  35
Table 2b. Contingency table showing accuracy of 2D CEUS vs CTA.
2D CEUS CTA
Endoleak
(yes)
Endoleak
(no)
Endoleak
(yes)
17 1 Positive predictive
value (94%)
Endoleak
(no)
0 12 Negative predictive
value (100%)
Sensitivity
(100%)
Speciﬁcity
(92%)
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greater than ultrasound (6.0  0.97). The interobserver
reliability of 3D CEUS was an almost perfect agreement
between two observers (Kappa ¼ 0.88; 95% CI 0.718 to 1.0;
p  .0001).
3D CEUS classiﬁed all endoleaks accurately; one patient
had both Type Ib and Type II endoleaks. 3D CEUS detected
the inﬂow artery in all 18 patients with endoleak. 2D CEUS
detected the inﬂow site in 16 (88.8%) and CTA on 12
(66.6%) images. CTA could not differentiate between Type II
and Type III in four cases, and in one case between Types Ib
and II. 2D CEUS failed to classify two endoleaks between
Type Ib, Type II, or Type III (Table 3).
One patient had an expanding 9 cm AAA with oscillating
thrombus but no colour ﬂow in the aneurysm detected on
2D ultrasound, which would be indicative of an intermittent
endoleak. CTA also failed to identify an endoleak. 3D CEUS
showed a Type Ib endoleak, tracking along the postero-
lateral edge of the aneurysm with the outﬂow into a lum-
bar artery. Following multidisciplinary team (MDT) discus-
sion, this was treated by relining the left iliac limb and
bilateral iliac limb extensions. Postoperative angiography
and 3D CEUS conﬁrmed that the endoleak had been
excluded.
DISCUSSION
Our pilot study was the ﬁrst to investigate 3D CEUS for the
detection of an endoleak following EVAR. 3D CEUS was
superior to both 2D CEUS and CTA in the identiﬁcation of
the inﬂow source. The results of this study also show that
3D CEUS had similar sensitivity and speciﬁcity to 2D CEUS
for detection of endoleaks, and may be more sensitive thanTable 2a. Contingency table showing accuracy of 3D CEUS vs CTA.
3D CEUS CTA
Endoleak
(yes)
Endoleak
(no)
Endoleak (yes) 17 1 Positive Predictive
Value (94%)
Endoleak (no) 0 12 Negative Predictive
Value (100%)
Sensitivity
(100%)
Speciﬁcity
(92%)CTA. This pilot study provides valuable information to advise
the design of a deﬁnitive study to determine the clinical
place of 3D CEUS in EVAR surveillance. 3D CEUS was per-
formed initially when there was clinical suspicion of an
endoleak; therefore data relating to ‘3D CEUS speciﬁcity’
were based on only 10 subjects with no endoleak. A larger
study is required to explore speciﬁcity. The interval between
paired images was an average of 3.9 weeks (range: same
day to 8 weeks). This study is based on paired images rather
than individual patients.16 Therefore, 30 paired images from
23 patients were analysed.
Conventional imaging failed to identify an endoleak in a
patient with an expanding AAA 6 years following EVAR; CTA
did not detect any endoleak during arterial or late phase
acquisition and 2D CEUS did not identify colourﬂow outside
the endograft. Non-contrast greyscale duplex identiﬁed
thrombus movement adjacent to an iliac limb, extending
from the ﬂow divider to the aortic bifurcation, raising the
suspicion of an intermittent endoleak because of thrombus
movement being the only clue. Finally, 3D CEUS showed a
Type Ib endoleak, which was discussed at the MDT and
subsequently treated successfully.
Our results on the accuracy of CEUS were consistent with
the recently published meta-analysis reporting the accuracy
of the duplex ultrasound, 2D CEUS, and CTA for surveillance
following EVAR.7 2D CEUS may be superior to both duplex
ultrasound without contrast and CTA for this purpose.17 CTAFigure 3. Correlation in post-EVAR sac size measured by CT and 3D
CEUS (Pearson’s r ¼ .935; p  .0001).
Table 3. 3D CEUS classiﬁed all endoleaks accurately.
Type of endoleak CTA 2D CEUS 3D CEUS
All endoleaks 17 18 18
Type 1 1?a 1 1
Type 2 12 15 17
Type 3 4?a 2a None
Type 4 None None None
Type 5 None None None
a CTA could not differentiate in four cases between Type 2 or Type
3 and in one case between Type 1 and 2. 2D CEUS failed to classify
endoleak accurately in two patients.
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endoleaks when compared with 2D CEUS (sensitivity 96%;
speciﬁcity 85%).7 In our pilot study, there was an excellent
correlation between post-EVAR AAA diameter measured by
CTA and ultrasound, but diameter measured by CTA was
greater than ultrasound and this is in keeping with pub-
lished literature.16
CEUS has the advantage that dynamic imaging may
classify endoleaks with more certainty than CTA, the di-
rection of ﬂow can often be seen. Duplex ultrasound helps
in visualising the ﬂow within renal arteries and also
identiﬁes blood ﬂow disturbance caused by stent-graft
deformation. 3D CEUS allows a reconstruction of these
images that is easier to interpret than CTA or 2D CEUS.
Moreover, 3D CEUS can be performed within a vascular
clinic setting and results are available immediately for
review. An operator experienced with vascular ultrasound
and CEUS, can learn to use and interpret the 3D images
during a 1 day training session. The limitation of CEUS is
that it does not visualise stent-graft migration or fracture,
although this is resolved by adding a plain X-ray to detect
graft migration in a CEUS-based EVAR surveillance
programme.
Although CTA is non-invasive, the cumulative nephro-
toxicity of contrast media and radiation exposure are major
side effects.18 Conversely, ultrasound is entirely safe and
non-invasive; ultrasound contrast can be used repeatedly
for surveillance, although caution is advised in subjects with
coronary artery disease and heart failure because of risk of
pre-mature ventricular contractions.9,19,20 It is eliminated
from the body by the lungs.9 The disadvantage of ultra-
sound is that the aorta may be difﬁcult to visualise because
of obesity or bowel gas.
EVAR surveillance is time-consuming and costly; a com-
parison of the clinical and cost effectiveness of 3D CEUS-
based surveillance with CTA-based surveillance will have a
major impact on the management of patients following
EVAR. Duplex ultrasound-based surveillance has been re-
ported to be less expensive than CTA-based surveillance
after EVAR.10,21,22 In our institution, the EVAR surveillance
programme entails CTA at 3 months and 1 year post-EVAR
and annual 2D duplex thereafter. 3D CEUS is performed if
an endoleak is suspected. In comparison with CTA only
annual surveillance, this has afforded a 67% reduction in
surveillance cost (CTA ¼ £250; 3D CEUS including
contrast ¼ £108).CONCLUSION
3D CEUS was more sensitive than CTA for the detection of
the source and outﬂow in endoleak following EVAR. Inter-
vention and treatment of endoleak depends on this infor-
mation. A deﬁnitive study is required to explore the role
and cost effectiveness of 3D CEUS in EVAR surveillance.
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